Stay updated on Subcutaneous vs. Intravenous Daratumumab in Myeloma Clinical Trial
Sign up to get notified when there's something new on the Subcutaneous vs. Intravenous Daratumumab in Myeloma Clinical Trial page.
Latest updates to the Subcutaneous vs. Intravenous Daratumumab in Myeloma Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe website has been updated from version 2.13.2 to 2.13.3.SummaryDifference0.3%
- Check19 days agoChange DetectedThe website has been updated from version v2.12.2 to v2.13.2, indicating a new release with potential improvements or features.SummaryDifference0.3%
- Check26 days agoNo Change Detected
- Check33 days agoChange DetectedThe website has added new features for data download options, while several key government health-related links and extensive data field descriptions have been removed.SummaryDifference14%
- Check41 days agoChange DetectedNew resources have been added, including links to HHS, NIH, NLM, NCBI, and USA.gov, enhancing the website's informational offerings.SummaryDifference0.7%
- Check48 days agoChange DetectedThe website has been updated to version v2.12.2, introducing new download options in various file formats and enhanced data field selection for studies.SummaryDifference16%
- Check55 days agoChange DetectedThe website has been updated from version 2.12.0 to 2.12.1.SummaryDifference0.3%
Stay in the know with updates to Subcutaneous vs. Intravenous Daratumumab in Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Subcutaneous vs. Intravenous Daratumumab in Myeloma Clinical Trial page.